Peptide

Eloralintide

Also known as

LY3841136 · Elo / Elora (forum shorthand) · Lilly selective amylin · SARA (selective amylin receptor agonist talk)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Amylin peptide	An investigational weight-management injection, also called Elo or Elora, that targets an amylin fullness signal rather than acting as another GLP-1.
Separate products	Pramlintide, cagrilintide and petrelintide are different identities. Eloralintide alone also differs from tirzepatide combinations and blinded macupatide assignments.

Notes

Eloralintide, also called Elo or Elora, is an investigational peptide injection for weight management. People discuss getting full sooner and thinking about food less. Reports also include delayed nausea, fatigue, bloating and little noticeable change; trial participants and people using unverified products describe different situations.

An amylin signal, rather than another GLP-1. Amylin is a hormone released after eating that helps signal fullness. Eloralintide, formerly LY3841136, preferentially activates the amylin 1 receptor. It is being studied as a once-weekly injection beneath the skin, not an oral supplement or stimulant. Lilly: What to know about eloralintide (Official context · Accessed 2026-09-30)

Related names do not mean interchangeable products. Pramlintide is discussed in mealtime micrograms; Eloralintide reports use milligrams. Cagrilintide, CagriSema and petrelintide are different identities. Eloralintide alone is also different from Lilly's investigational EloraTZP combination with tirzepatide or a blinded eloralintide/macupatide assignment. Lilly: What to know about eloralintide (Official context · Accessed 2026-09-30) · Week 1 Update: Eloralintide and Macupatide Phase 2b Trial (Personal report · Accessed 2026-09-30)

Source context — Lilly: What to know about eloralintide: Manufacturer communications with commercial interests. Describes investigational identity and program; not independent comparison, approved use or proof for unverified products.

Source context — Week 1 Update: Eloralintide and Macupatide Phase 2b Trial: Assignment unknown among placebo, macupatide, Eloralintide and combinations. Dietitian and exercise support confound weight change. Cross-post in r/Eloralintide is the same story, not a second user. Injection volume does not disclose active milligrams.

What people notice

Full sooner, less food noise	Some describe stopping after a few bites or fewer cravings. A blinded participant's unknown assignment prevents calling that an Eloralintide-only result.
Plateaus and no change	One trial diary reports weight loss followed by plateaus, with 9 mg feeling weaker than 6 mg. Informal users also report nothing after 1 mg or four days.
Too full to enjoy food	One diarist still wanted food mentally while feeling too bloated to eat. Better appetite control can coexist with fatigue and discomfort.

Notes

Less hunger and fewer automatic food decisions. One blinded participant described stopping meals after a few bites and needing reminders to eat. A separate trial diary described fewer cravings and easier food changes. These accounts describe appetite and behavior, not proof of an isolated Eloralintide effect. Week 1 Update: Eloralintide and Macupatide Phase 2b Trial (Personal report · Accessed 2026-09-30) · LaCipe: Sharing my experience, weeks 11–12 (Personal report · Accessed 2026-09-30)

Leather_Formal1080 OP and same-author replies: days 1–5, week three, weekly home injection, blinded volumes and 4½-week follow-up; lines 18–32, 67–76, 88–94, 164–186, 255–287. Week 1 Update: Eloralintide and Macupatide Phase 2b Trial (Personal report · Accessed 2026-09-30)

Physical fullness and wanting food can separate. LaCipe described wanting a pleasant meal mentally while feeling too bloated to eat, and losing food as an outlet for stress or boredom. Later, the same diary reported 15 kg lost, then another plateau at 14–15 kg with 9 mg feeling weaker than 6 mg. This is one evolving account. LaCipe: Sharing my experience, weeks 9–10 (Personal report · Accessed 2026-09-30) · LaCipe: Sharing my experience, weeks 11–12 (Personal report · Accessed 2026-09-30) · LaCipe: Sharing my experience, weeks 12–14 (Personal report · Accessed 2026-09-30)

Nonresponse and enthusiasm coexist. The dosing thread includes users feeling nothing after 1 mg or four days, alongside an enthusiastic user who found combining with tirzepatide too strong by week three. One nonresponder questioned product legitimacy. Neither a quiet response nor strong fullness verifies what was injected. Eloralintide dosing: starts, trial-sequence disagreement and quiet responses (Community discussion · Accessed 2026-09-30)

Better tolerability and muscle preservation are hopes, not guarantees. MESO-Rx discussion extrapolates less nausea and better muscle preservation from animal comparisons with cagrilintide. That is animal-derived speculation, not a demonstrated human advantage. Other accounts describe substantial fatigue and bloating despite appetite benefits. MESO-Rx: Eloralintide Phase 2 Data is Out (Secondhand community claim · Accessed 2026-09-30) · Officially in ENLIGHTEN-6: former participant's retrospective replies (Personal report · Accessed 2026-09-30) · LaCipe: Sharing my experience, weeks 9–10 (Personal report · Accessed 2026-09-30)

Source context — LaCipe: Sharing my experience, weeks 11–12: Same self-described trial diarist. No starting weight disclosed; kilogram change cannot yield a percent or establish composition. Former card classified this dose as gray; surrounding trial discussion contradicts that framing.

Source context — LaCipe: Sharing my experience, weeks 9–10: Same LaCipe diary as other weeks, not separate corroboration. Meal volume and repeated treatment determine context; the hours are not injection duration. Uncertain trial dose/assignment remains.

Source context — LaCipe: Sharing my experience, weeks 12–14: Same person's later follow-up. Future plateau recovery is an expectation, not observed here. Remembered 0.5/3/6/9 and anticipated 12 mg are not verified protocol facts. Shoe anecdote omitted as peripheral.

Source context — Eloralintide dosing: starts, trial-sequence disagreement and quiet responses: Unverified injections, co-use, advice and opinion intermixed. Exclude vendor/sourcing content. evan230 tolerance-break comment has ambiguous drug referent and is not an Eloralintide restart record. _Vlxd_ enthusiasm is not proof of synergy or safety.

Source context — MESO-Rx: Eloralintide Phase 2 Data is Out: Strong pro-compound opinion, unsupported human extrapolation and supplier promotion. Opened first page, not entire thread or linked rat abstract. Animal origins are retained explicitly; sourcing passages excluded.

Source context — Officially in ENLIGHTEN-6: former participant's retrospective replies: Retrospective unverified treatment history, unspecified high/low milligram doses, unequal exposures. One person's benefit, adverse effects and regain form one timeline.

Doses people talk about

One weekly combination	1 mg Eloralintide added to 10 mg tirzepatide weekly appears in one unverified account, rather than a validated starting schedule.
Different interval	0.5 mg every four days is a separate unverified combination account, not an equivalent weekly schedule.
Weekly trial sequences	1, 3, 6, 9 mg and 1.5, 3, 6, 9 mg circulate in different trial discussions. Study identity and blinded assignment matter; these are not home escalation instructions.
Volumes without active amounts	A blinded diarist reported 0.3 then 0.6 mL for the Eloralintide-labeled injection and 0.5 mL for macupatide weekly. Active milligrams remained unknown.

Notes

1 mg once weekly appears in informal starting accounts. One commenter reported adding 1 mg to 10 mg tirzepatide weekly. Another reported 0.5 mg every four days. These are separate, unverified combination accounts; neither supplies a validated starting amount or equivalent weekly schedule. Eloralintide dosing: starts, trial-sequence disagreement and quiet responses (Community discussion · Accessed 2026-09-30) · Eloralintide Starting Dose? Looking for User Experiences (Community discussion · Accessed 2026-09-30)

1, 3, 6, 9 mg and 1.5, 3, 6, 9 mg circulate as different weekly trial sequences. Commenters disagree about the first step and which study they mean. A participant's reported 6 mg, later 9 mg, belongs to a trial diary, not a confirmed gray-product dose. Trial labels and blinded assignment do not necessarily identify active treatment. Eloralintide dosing: starts, trial-sequence disagreement and quiet responses (Community discussion · Accessed 2026-09-30) · LaCipe: Sharing my experience, weeks 8–9 (Personal report · Accessed 2026-09-30) · LaCipe: Sharing my experience, weeks 11–12 (Personal report · Accessed 2026-09-30) · LaCipe: Sharing my experience, weeks 12–14 (Personal report · Accessed 2026-09-30)

Injection volume is not the active-drug amount. The blinded diarist reported 0.3 mL, later 0.6 mL, for the Eloralintide-labeled injection and 0.5 mL for macupatide, each weekly. Active doses remained unknown. Those volumes cannot supply milligram amounts or an ingredient ratio without the formulation and assignment. Week 1 Update: Eloralintide and Macupatide Phase 2b Trial (Personal report · Accessed 2026-09-30)

Source context — Eloralintide Starting Dose? Looking for User Experiences: Unverified amounts, trial hearsay, combination confounding. Do not copy mealtime pramlintide quantities or treat daily/four-day/weekly mentions as equivalent. Sourcing requests excluded.

Source context — LaCipe: Sharing my experience, weeks 8–9: Self-described trial participant; dose knowledge and active assignment uncertain. Fatigue improvement after another medicine lapse cannot establish causality. The old later '6 mg Elo only' account must not be called gray-market solely because it appears on Reddit.

Half-life, onset & duration

Felt onset	One stacked user recalled effects around day 4–5 after initially quiet days; this is not a measured peak rule.
Felt duration	No dependable one-injection window is established. A diary's 6–7 hours of fullness after a smoothie describes a meal during ongoing treatment.
Half-life	Roughly 14 days in the human Phase 1 paper. Circulated 10–14-day and 15-day figures are not users measuring appetite or nausea duration.

Notes

Quiet early days can precede later effects. One stacked account described little initially, then nausea on Tuesday after Saturday's 1 mg injection. In another thread, the same username recalled noticing effects around day 4–5. Other commenters still felt nothing on day four. A repeated 4–5-day peak claim is not a measured onset rule. Started on Saturday 1 mg, waves of nausea Tuesday (Personal report · Accessed 2026-09-30) · Eloralintide dosing: starts, trial-sequence disagreement and quiet responses (Community discussion · Accessed 2026-09-30)

Repeated-use diaries do not establish one-dose duration. The blinded diary's appetite reduction continued into week three, then eased somewhat by about 4½ weeks. A separate trial diary described fullness lasting 6–7 hours after a smoothie, easing around 14 hours. That is a meal experience during ongoing treatment, not the duration of one injection. Week 1 Update: Eloralintide and Macupatide Phase 2b Trial (Personal report · Accessed 2026-09-30) · LaCipe: Sharing my experience, weeks 9–10 (Personal report · Accessed 2026-09-30)

Human measurements stay separate from forum schedules. The Phase 1 paper describes a roughly 14-day half-life. Phase 2 studied 1, 3, 6 and 9 mg weekly, plus 6-to-9 and 3-to-6-to-9 mg escalation arms. Higher-dose stomach symptoms and fatigue were more frequent; slower escalation reduced them. These are study conditions, not a personal schedule. Bhattachar et al.: Phase 1 proof of concept (Official context · Accessed 2026-09-30) · Lilly: 48-week Phase 2 Eloralintide results (Official context · Accessed 2026-09-30)

10–14 days, about 14 days, and 15 days are circulated figures. A Reddit user repeated 10–14 days, a dosing thread said 14, and Peptide Critic commenters discussed a 15-day chart. The roughly two-week figure originates in human Phase 1 work, not users measuring their own half-life. Half-life means the time for the body's amount to fall by half; it is not a nausea or appetite clock. Started on Saturday 1 mg, waves of nausea Tuesday (Personal report · Accessed 2026-09-30) · Eloralintide dosing: starts, trial-sequence disagreement and quiet responses (Community discussion · Accessed 2026-09-30) · Peptide Critic: Eloralintide chart half-life discussion (Secondhand community claim · Accessed 2026-09-30)

Source context — Started on Saturday 1 mg, waves of nausea Tuesday: Unverified product and simultaneous retatrutide, testosterone, HCG, MOTS-C, GHK-Cu and KPV. Same username also appears in the dosing thread; not independent corroboration. Claims about 10–14-day half-life and 4–5-day peak are secondhand.

Source context — Bhattachar et al.: Phase 1 proof of concept: Sponsor-authored small human trial, 12 weeks, adults with overweight/obesity. Roughly 14 days is human research context, not felt duration. Exact 13.9–15.8-day ADA range is not freshly verified. Wiley and PMC versions are the same source family.

Source context — Lilly: 48-week Phase 2 Eloralintide results: Sponsor summary, not freshly opened Lancet full text. Efficacy estimand assumes continued intervention; adults without type 2 diabetes. Slower-escalation finding does not create a home protocol. PDF/PRNewswire mirrors share this source origin.

Source context — Peptide Critic: Eloralintide chart half-life discussion: Partial page body available despite deleted-topic notice. Underlying chart not opened; number is repetition, not pharmacokinetic measurement. Commercial surroundings and vendor assurances cannot prove product quality.

Cycles people discuss

Continued treatment	One informal user planned four weeks at 1 mg before reassessing; trial diaries span months. No settled on/off, maintenance or tolerance-reset schedule emerges.
After a trial	One former participant described regain after treatment ended, followed by low-dose tirzepatide maintenance. That is one transition rather than a general withdrawal pattern.

Notes

Weeks of continued treatment appear; a settled on/off cycle does not. One informal user planned four weeks at 1 mg before reassessing. Trial diaries span months. Those timelines and circulated monthly increases are not proof of an optimal course, maintenance schedule or tolerance reset. Started on Saturday 1 mg, waves of nausea Tuesday (Personal report · Accessed 2026-09-30) · Eloralintide dosing: starts, trial-sequence disagreement and quiet responses (Community discussion · Accessed 2026-09-30) · LaCipe: Sharing my experience, weeks 12–14 (Personal report · Accessed 2026-09-30)

Weight regain after a trial is part of the story. A former participant described starting to regain after treatment ended, then maintaining weight on low-dose tirzepatide. This is one person's transition, not a demonstrated withdrawal pattern. Reliable Eloralintide-only missed-dose and restart diaries remain sparse. Officially in ENLIGHTEN-6: former participant's retrospective replies (Personal report · Accessed 2026-09-30)

Stacks

Tirzepatide	Both investigational combination work and informal co-use appear. One enthusiastic user found the combination too strong by week three.
Macupatide	A blinded trial diary involved Eloralintide, macupatide, their combination or placebo; the assignment was unknown.
Larger informal stack	One delayed-nausea account also involved retatrutide, testosterone, hCG, MOTS-c, GHK-Cu and KPV. It cannot isolate an Eloralintide effect or interaction.

Notes

Tirzepatide research: Lilly combination work discussed in 2026 is investigational. Neither those studies nor informal co-use establishes a home combination protocol. [trial]

OP mergingcultures, opening stack list and Saturday/Tuesday account; replies planning four weeks at 1 mg and later second-dose fullness without fatigue; web text lines 17–34, 63–76, 108–118, 153–162. Started on Saturday 1 mg, waves of nausea Tuesday (Personal report · Accessed 2026-09-30)

Watch for

Stomach symptoms and fatigue	Nausea, bloating, constipation and marked fatigue are reported. Reduced eating and rapid weight loss are concerns; less nausea is not a guarantee of easy eating.
Mood events in research	Phase 1 reported mood-related events in three people in the 12 mg cohort. They resolved 2–4 days after treatment stopped; this is not a community risk rate.
Product and safety gaps	Trial injections and marketplace vials are different settings. Identity, interactions, pregnancy, breastfeeding and long-term safety are not settled by these accounts.

Notes

Less nausea does not mean no nausea, or easy eating. Reports include nausea waves, bloating, constipation and fatigue. One unlinked account described severe first-week nausea with a 12 lb drop. Existing discussion also flags inadequate food intake and gallbladder concerns during rapid loss; these reports do not establish Eloralintide-specific risk rates. Started on Saturday 1 mg, waves of nausea Tuesday (Personal report · Accessed 2026-09-30) · Week 1 Update: Eloralintide and Macupatide Phase 2b Trial (Personal report · Accessed 2026-09-30)

Mood changes also deserve attention. Human Phase 1 work reported mood-related events in three people in the 12 mg cohort; treatment was stopped and the events resolved within 2–4 days. Those observations are not a community incidence estimate or evidence that smaller amounts eliminate the concern. Bhattachar et al.: Phase 1 proof of concept (Official context · Accessed 2026-09-30)

A marketplace name does not establish identity or safety. Trial injections and vials labeled Elo are different evidence settings. Multi-agent use obscures interactions and attribution. Refrigeration lore is not validated stability information. These accounts cannot establish pregnancy or breastfeeding safety, long-term safety, or a dependable home combination protocol. Started on Saturday 1 mg, waves of nausea Tuesday (Personal report · Accessed 2026-09-30)

Full notes

What Eloralintide actually is

An amylin signal, rather than another GLP-1. Amylin is a hormone released after eating that helps signal fullness. Eloralintide, formerly LY3841136, preferentially activates the amylin 1 receptor. It is being studied as a once-weekly injection beneath the skin, not an oral supplement or stimulant. Official context Community
Related names do not mean interchangeable products. Pramlintide is discussed in mealtime micrograms; Eloralintide reports use milligrams. Cagrilintide, CagriSema and petrelintide are different identities. Eloralintide alone is also different from Lilly's investigational EloraTZP combination with tirzepatide or a blinded eloralintide/macupatide assignment. Community Official context Personal report

What people hope to get from it

Less hunger and fewer automatic food decisions. One blinded participant described stopping meals after a few bites and needing reminders to eat. A separate trial diary described fewer cravings and easier food changes. These accounts describe appetite and behavior, not proof of an isolated Eloralintide effect. Personal report Personal report
Weight loss, with plateaus still possible. Lilly's 263-person Phase 2 study reported mean losses of 9.5–20.1% across arms over 48 weeks, versus 0.4% with placebo, under an analysis assuming continued treatment. A participant diary still described plateaus and a higher reported dose feeling less effective. Trial averages do not predict an individual result. Official context Personal report
Better tolerability and muscle preservation are hopes, not guarantees. MESO-Rx discussion extrapolates less nausea and better muscle preservation from animal comparisons with cagrilintide. That is animal-derived speculation, not a demonstrated human advantage. Other accounts describe substantial fatigue and bloating despite appetite benefits. MESO-Rx Personal report Personal report

Doses people discuss

Reported amounts describe discussions, not a regimen. mg means milligrams; 1 mg equals 1,000 micrograms. These injection amounts are per administration unless a frequency is given.

1 mg once weekly appears in informal starting accounts. One commenter reported adding 1 mg to 10 mg tirzepatide weekly. Another reported 0.5 mg every four days. These are separate, unverified combination accounts; neither supplies a validated starting amount or equivalent weekly schedule. Reddit r/Eloralintide Reddit r/Eloralintide
1, 3, 6, 9 mg and 1.5, 3, 6, 9 mg circulate as different weekly trial sequences. Commenters disagree about the first step and which study they mean. A participant's reported 6 mg, later 9 mg, belongs to a trial diary, not a confirmed gray-product dose. Trial labels and blinded assignment do not necessarily identify active treatment. Reddit r/Eloralintide Personal report Personal report Personal report Community
Injection volume is not the active-drug amount. The blinded diarist reported 0.3 mL, later 0.6 mL, for the Eloralintide-labeled injection and 0.5 mL for macupatide, each weekly. Active doses remained unknown. Those volumes cannot supply milligram amounts or an ingredient ratio without the formulation and assignment. Personal report

Half-life

10–14 days, about 14 days, and 15 days are circulated figures. A Reddit user repeated 10–14 days, a dosing thread said 14, and Peptide Critic commenters discussed a 15-day chart. The roughly two-week figure originates in human Phase 1 work, not users measuring their own half-life. Half-life means the time for the body's amount to fall by half; it is not a nausea or appetite clock. Personal report Reddit r/Eloralintide Peptide Critic Community Community

Onset: when a change is noticed

Quiet early days can precede later effects. One stacked account described little initially, then nausea on Tuesday after Saturday's 1 mg injection. In another thread, the same username recalled noticing effects around day 4–5. Other commenters still felt nothing on day four. A repeated 4–5-day peak claim is not a measured onset rule. Personal report Reddit r/Eloralintide
Early fatigue and stomach discomfort can settle while appetite changes continue. The blinded-trial author reported day-one cramping, fatigue resolving by days 4–5, constipation and no nausea or vomiting. Appetite remained lower at week three. Unknown assignment prevents attributing that sequence specifically to Eloralintide. Personal report

Duration: how long the experience lasts

Repeated-use diaries do not establish one-dose duration. The blinded diary's appetite reduction continued into week three, then eased somewhat by about 4½ weeks. A separate trial diary described fullness lasting 6–7 hours after a smoothie, easing around 14 hours. That is a meal experience during ongoing treatment, not the duration of one injection. Personal report Personal report

Cycles, stopping and restarting

Weeks of continued treatment appear; a settled on/off cycle does not. One informal user planned four weeks at 1 mg before reassessing. Trial diaries span months. Those timelines and circulated monthly increases are not proof of an optimal course, maintenance schedule or tolerance reset. Personal report Reddit r/Eloralintide Personal report
Weight regain after a trial is part of the story. A former participant described starting to regain after treatment ended, then maintaining weight on low-dose tirzepatide. This is one person's transition, not a demonstrated withdrawal pattern. Reliable Eloralintide-only missed-dose and restart diaries remain sparse. Personal report Community

What can change the experience

Less nausea does not mean no nausea, or easy eating. Reports include nausea waves, bloating, constipation and fatigue. One unlinked account described severe first-week nausea with a 12 lb drop. Existing discussion also flags inadequate food intake and gallbladder concerns during rapid loss; these reports do not establish Eloralintide-specific risk rates. Personal report Personal report Community Community
Mood changes also deserve attention. Human Phase 1 work reported mood-related events in three people in the 12 mg cohort; treatment was stopped and the events resolved within 2–4 days. Those observations are not a community incidence estimate or evidence that smaller amounts eliminate the concern. Official context
A marketplace name does not establish identity or safety. Trial injections and vials labeled Elo are different evidence settings. Multi-agent use obscures interactions and attribution. Refrigeration lore is not validated stability information. These accounts cannot establish pregnancy or breastfeeding safety, long-term safety, or a dependable home combination protocol. Community Community Personal report

Community: fullness, fatigue and uneven results

Physical fullness and wanting food can separate. LaCipe described wanting a pleasant meal mentally while feeling too bloated to eat, and losing food as an outlet for stress or boredom. Later, the same diary reported 15 kg lost, then another plateau at 14–15 kg with 9 mg feeling weaker than 6 mg. This is one evolving account. Personal report Personal report Personal report
Fatigue has competing explanations. LaCipe felt better after accidentally running out of spironolactone, but that does not prove an interaction or justify stopping blood-pressure treatment. A former participant recalled marked fatigue on higher-dose Eloralintide, less fatigue on lower-dose tirzepatide, and better nighttime craving control with Eloralintide. The unequal doses limit the comparison. Personal report Personal report
Nonresponse and enthusiasm coexist. The dosing thread includes users feeling nothing after 1 mg or four days, alongside an enthusiastic user who found combining with tirzepatide too strong by week three. One nonresponder questioned product legitimacy. Neither a quiet response nor strong fullness verifies what was injected. Reddit r/Eloralintide

Supporting human research context

Human measurements stay separate from forum schedules. The Phase 1 paper describes a roughly 14-day half-life. Phase 2 studied 1, 3, 6 and 9 mg weekly, plus 6-to-9 and 3-to-6-to-9 mg escalation arms. Higher-dose stomach symptoms and fatigue were more frequent; slower escalation reduced them. These are study conditions, not a personal schedule. Official context Official context